A comparative analysis of the role and impact of Health Technology Assessment


Over the last ten years, Health Technology Assessment (HTA) has become an increasingly important part of the assessment system for new medicines. It is generally agreed that HTA has the potential to assist payers in making informed decisions about allocating resources (including expenditure on medicines) in the health system. However, it is also possible that a poorly designed or managed HTA process runs the risk of denying patients appropriate access to medical technologies, inefficiently allocating resources, constraining clinical freedom and sending distorted signals to medical technology providers.

To this end a considerable amount of effort has been put into developing best practice principles which demonstrate a degree of consensus  between academia, payers and industry. Charles River Associates (“CRA”) was asked by EFPIA, PhRMA, Medicines Australia and EuropaBio to undertake a comparative assessment of the role and impact of Health Technology Assessment (HTA) in different parts of the world. In this report, we use these principles to compare how different systems use HTA, the basis of the approach they apply, how it works in practice and the consequences for the key stakeholders.